HR positive + HER-2 positive

BRD8 regulated ER-dependent and independent growth pathways, and depletion of BRD8 abolished neratinib-induced ER activation and restored drug sensitivity in resistant cells. A 3-gene BRD8 signature successfully predicted anti-HER2 therapy response in two human clinical trials. Together, these findings establish BRD8 as both a predictive biomarker for anti-HER2 response and a therapeutic target to overcome resistance in HR+/HER2+ breast cancer.

Locally advanced and metastatic thymic carcinoma remains challenging to manage, making this patient's response particularly noteworthy. Given that the therapeutic strategies for thymic tumors have remained largely unchanged in recent years, dose-dense chemotherapy may represent a promising addition to the current treatment paradigm, though further investigation is needed to evaluate its broader applicability.

While prospective validation remains limited, these technologies may help redefine surgical candidacy through biologically informed algorithms. Ultimately, the integration of surgery within a multimodal, personalized treatment strategy-guided by systemic control, tumor biology, and evolving digital tools-represents an evolving and biologically informed direction for rigorously selected patients with visceral breast cancer metastases.

In asymptomatic patients at recurrence, the first distant recurrence was detected significantly earlier using imaging modalities than using blood tests. Conclusion Symptom status at first distant breast cancer recurrence may be associated with post-recurrence survival, with asymptomatic recurrence showing more favorable outcomes.

P=N/A, N=200, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy, with increased toxic effects, mainly neutropenia. (Funded by Pfizer and others; PATINA ClinicalTrials.gov number, NCT02947685.).

P2, N=35, Not yet recruiting, Xijing Hospital

Young Black women were more likely than White women to elect the less-invasive surgery (lumpectomy). Private insurance was associated with better OS and RFS.

OFS + AI were associated with better DDFS in patients with RD after neoadjuvant therapy. Our findings can assist shared decision-making on adjuvant endocrine therapy of these patients.

With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations.

P2, N=362, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Phase classification: P1 --> P2